This 2006 review by Dr. Ralph M. Trüeb addresses the biological and environmental contributors to hair aging, including genetic factors, hormonal changes, oxidative stress, and UV radiation. The article outlines established pharmacologic treatments such as topical minoxidil and oral finasteride, which are effective for androgenetic alopecia and age-related hair thinning.
This 2018 systematic review and network meta-analysis evaluated the comparative effectiveness of six non-surgical treatments for androgenetic alopecia (AGA): dutasteride 0.5 mg, finasteride 1 mg, low-level laser therapy (LLLT), minoxidil 2%, minoxidil 5%, and platelet-rich plasma (PRP). The review included 78 studies, with 22 qualifying for quantitative synthesis. LLLT demonstrated
This 2019 systematic review evaluated the use of finasteride in women for treating hair disorders such as female pattern hair loss (FPHL), frontal fibrosing alopecia (FFA), and lichen planopilaris. It included various study designs—mainly observational—with treatment doses ranging from 0.5 mg to 5 mg daily and durations spanning 6 to
This 2013 cohort study analyzed 1,315 men who underwent radical prostatectomy between 1995 and 2009 to assess the impact of 5α-reductase inhibitors (5-ARIs) and alpha-blockers on tumor grade and biochemical recurrence. Long-term use (≥4 years) of 5-ARIs (finasteride or dutasteride) was associated with a higher proportion of high-grade tumors (Gleason
This 2012 observational study published in the Journal of Clinical Psychiatry (PMID: 22939118) examined the mental health of 61 former finasteride users who developed persistent sexual side effects after discontinuation. Results showed that 75% of these men had depressive symptoms (BDI-II ≥ 14), and 44% reported suicidal thoughts—dramatically higher than
This review article explores Post-Finasteride Syndrome (PFS), a condition characterized by persistent sexual, neurological, physical, and psychological side effects that can occur during or after discontinuation of finasteride or dutasteride, commonly prescribed for androgenetic alopecia or benign prostatic hyperplasia. The review identifies significant adverse effects such as sexual dysfunction, depression,
This 2012 randomized controlled trial published in the Journal of the Medical Association of Thailand (PMID: 23193746) evaluated the efficacy and safety of 3% minoxidil (MNX) versus a combination of 3% minoxidil and 0.1% finasteride (MFX) in 40 men with androgenetic alopecia (AGA) over 24 weeks. The MFX group showed
This 5-year placebo-controlled study investigated the natural progression of androgenetic alopecia (AGA) in men, showing a 26.3% reduction in scalp hair density (loss of 239 hairs) and visible worsening in 75% of participants by year five. The study highlights the consistent and progressive nature of hair loss in untreated individuals,
This 24-month randomized controlled trial (PMID: 12695131) assessed the efficacy and tolerability of finasteride 1 mg daily in 424 men aged 41–60 with mild-to-moderate vertex male pattern hair loss. Finasteride significantly improved hair growth compared to placebo starting at month 6 (p < 0.001) and continued through month 24, as
This randomized controlled trial compared dutasteride (0.5 mg) and finasteride (1 mg) in men aged 18–40 with androgenetic alopecia (AGA) over 24 weeks. Dutasteride showed significantly superior results in increasing hair count and reducing hair miniaturization compared to finasteride, with similar safety profiles. Both medications had mild to moderate adverse
